X0206 3 2017-11-01 0 0001624658 Allena Pharmaceuticals, Inc. ALNA 0001362099 Kraus Stephen C/O ALLENA PHARMACEUTICALS, INC. ONE NEWTON EXECUTIVE PARK, SUITE 202 NEWTON MA 02459 1 0 0 0 Stock Option (Right to Buy) 5.72 2027-09-26 Common Stock 20364 D Series A Preferred Stock Common Stock 0 I See Footnotes Series B Preferred Stock Common Stock 0 I See Footnotes These shares will vest annually over a 3 (three) year period beginning on September 26, 2018. The Reporting Person has agreed to assign to Deer Management Co. LLC the right to any shares issuable pursuant to the grant or any proceeds from the sale thereof. Each share of Series A Preferred Stock is convertible into Common Stock on a 4.174-for-one basis at any time at the holder's election, and automatically upon the closing of the Issuer's initial public offering, and has no expiration date. As of the date hereof, Bessemer Venture Partners VII Institutional L.P. ("BVP VII Inst"), Bessemer Venture Partners VII, L.P. ("BVP VII") and BVP VII Special Opportunity Fund L.P. ("BVP VII SOF" and together with BVP VII Inst and BVP VII, collectively, the "Funds"), own 205,350 shares, 469,376 shares, and 792,074 shares, respectively, of Common Stock issuable upon conversion of the Series A Preferred Stock. The Reporting Person has a passive economic interest in the shares held by the Funds through an interest in (1) BVP VII and (2) Deer VII & Co. L.P. ("Deer L.P."), the general partner of each of the Funds. The Reporting Person disclaims beneficial ownership of the securities held by the Funds, except to the extent of his pecuniary interest, if any, in such securities by virtue of his interest in Deer L.P. and his indirect limited partnership interest in BVP VII. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities. Each share of Series B Preferred Stock is convertible into Common Stock on a 4.174-for-one basis at any time at the holder's election, and automatically upon the closing of the Issuer's initial public offering, and has no expiration date. As of the date hereof, BVP VII Inst, BVP VII, and BVP VII SOF own 106,479 shares, 243,381 shares, and, 410,705 shares, respectively, of Common Stock issuable upon conversion of the Series B Preferred Stock. Exhibit 24 - Power of Attorney /s/ Kevin Brennan, attorney-in-fact 2017-11-01